Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma - 04/09/11
, Michikazu Terada, Maki Hozawa
Corresponding author. Tel.: +81 82 568 1167; fax: +81 82 568 1239.Abstract |
Background |
A course of combination therapy with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA) for asthma can improve lung function, asthma symptoms and reduce exacerbations. Because both medicinal substance and inhalation devices are associated with clinical efficacy, each ICS/LABA combination may have different features. This study aimed to compare the effects of two widely available formulations, budesonide/formoterol (BUD/FM) delivered by a Turbuhaler®, and fluticasone/salmeterol (FP/SM) delivered by a Diskus®, on small airway function and airway inflammation.
Methods |
Asthmatic patients (n = 40) treated twice daily with FP/SM 250/50 μg with forced expiratory volume in 1 s values controlled above 80% of the predicted normal but with suspected persistent airway inflammation and small airway impairment were enrolled in the study. Patients were randomized into two groups, receiving either twice daily BUD/FM 320/9 μg or FP/SM 250/50 μg, and treatment efficacy was compared after 4 weeks. Outcomes included impulse oscillometry (IOS), fractional exhaled nitric oxide (FeNO), spirometry and Asthma Control Questionnaire (ACQ) scores.
Results |
Patients in the BUD/FM group showed significant improvements in their IOS and spirometry parameters of small airway function, FeNO values and ACQ scores, compared with the FP/SM group. There were good correlations between IOS parameters, FeNO and ACQ score changes over the course of the treatment.
Conclusions |
BUD/FM twice daily significantly improved small airway impairment and airway inflammation in asthmatic patients, leading to a reduction in asthma symptoms and achievement of good asthma control. In addition, improvement of small airway function may improve airway inflammation and/or lead to better controlled asthma.
Le texte complet de cet article est disponible en PDF.Résumé |
Highlights |
► BUD/FM significantly improved small airway impairment better than FP/SM. ► BUD/FM significantly reduced airway inflammation more than FP/SM. ► Parameters of small airway, inflammation and asthma control were well correlated. ► Improvements of small airway may lead better inflammation level and asthma control.
Le texte complet de cet article est disponible en PDF.Keywords : Budesonide, Formoterol, Fluticasone, Salmeterol, Impulse oscillometry (IOS), Fractional exhaled nitric oxide (FeNO), Small airway
Plan
Vol 24 - N° 5
P. 571-576 - octobre 2011 Retour au numéro
Article précédent
- Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial
- Helgo Magnussen, Henrik Watz, Anne Kirsten, Millie Wang, Heather Wray, Viktoria Samuelsson, John Mo, Richard Kay
- Cell culture models using rat primary alveolar type I cells
- Charles A. Downs, David W. Montgomery, Carrie J. Merkle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?